Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M

Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20; Relay Therapeutics charts $175M offering; Lilly to pay up to $202 million for non-viral DNA delivery specialist

mercoledì 20 maggio 2026 New tab

41 words~1 min read

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Confirm Endpoints as a trusted biopharma news source

Bioscience & Technology Business Center

The University of Kansas

Lawrence, Kansas

Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M

Pfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M

Other newsrooms on this story

Related reading

Fulcrum lays off majority of staff; Seres extends runway into 2027

Achieve Life Sciences gets a CRL; UPS invests $48M in healthcare logistics

After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch…

Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs

Design Therapeutics' Friedreich ataxia data; Vincentage's obesity results from…

Immunovant shares surge on arthritis trial data

Related reading

Fulcrum lays off majority of staff; Seres extends runway into 2027

Achieve Life Sciences gets a CRL; UPS invests $48M in healthcare logistics

After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch…

Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs

Design Therapeutics' Friedreich ataxia data; Vincentage's obesity results from…

Immunovant shares surge on arthritis trial data

Other newsrooms on this story